Bonjour, | Log in
  • Français

Predilife
The company

See the interview with Stéphane Ragusa, CEO of Predilife

The company

Founded in 2004 by Stéphane Ragusa, Predilife has pioneered the design and development of prediction tests, giving everyone the chance to find out their own risk of developing serious diseases. It combines proven medical techniques with Artificial Intelligence and Big Data.

Predilife is a company at the heart of predictive medicine. Predictive medicine involves anticipating an individual’s future so that action can be taken in time thanks to personalised prevention, either by reducing risk, or by identifying the disease as early as possible. Serious conditions, such as cancer and heart attack, can be better prevented.

Since 2018, Predilife has been listed on Euronext.

Our vision

« The sooner the better ».

Stéphane Ragusa, CEO of Predilife, is a graduate of the prestigious École Polytechnique engineering school. For several years, he has implemented many innovations in the field of predictive and preventive medicine to enable men and women to anticipate their risk of developing serious diseases, and consequently to take action.

Our mission

Predilife develops predictive tests for the medicine of the future: Predictive, Preventive, Personalised and Participative (the 4 Ps). Predictive medicine involves anticipating an individual’s future so that action can be taken in time thanks to personalised prevention, either by reducing risk (known as primary prevention), or by identifying the disease as early as possible (secondary prevention).

Serious conditions, such as cancer and heart attack, can be better prevented.

Predilife is committed to respecting the General Data Protection Regulation (GDPR) and attaches particular importance to data security and preserving patients’ medical confidentiality..

The team

The Predilife Board, comprising Stéphane Ragusa, Pierre Verdet, Valérie Hélin and Émilien Gauthier, is supported by 5 developers, 8 employees and 8 sales representatives in France and abroad.

Stéphane Ragusa

Chief Executive Officer

Linkedin

Valérie Hélin

Chief medical officer

Linkedin

Émilien Gauthier

Chief Technology Officer

Linkedin

Marion Renelier

Legal Director

Linkedin

The history of Predilife

2004

Predilife founded
by Stéphane Ragusa

2007

Contract with INSERM for access to their cohorts of data

2013

Contract with BCSC (Breast Cancer Surveillance Consortium) for access to their database on 1,000,000 American women.

2017

First FDA agreement obtained for DenSeeMammo

Riviera study (NCT02997384) sponsored by Gustave Roussy and funded by ARC (Association for Cancer Research), aiming to show the acceptability and feasibility of breast cancer risk consultations in community practice.

2018

Predilife goes public. CE marking for MammoRisk and DenSeeMammo.

2019

The MyPeBS study is launched.
Access to the French and European market.

2020

Deployment of a sales team in France and Europe.

2021

CE marking of risk prediction medical devices for cancers: prostate, colon, lung and for heart attack

test test

Our historical partners

Back To Top